The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - IDEAYA Biosciences; Loxo
Consulting or Advisory Role - Guidepoint Global; OncoArt
Speakers' Bureau - Solti
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - START
 
Consulting or Advisory Role - Lilly
Research Funding - AstraZeneca; Genentech; Lilly; Pfizer; Radius Health; Sanofi
AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).
 
Sarat Chandarlapaty
Consulting or Advisory Role - BMS; Lilly; Novartis; Paige.ai; Sanofi; Sermonix Pharmaceuticals; Totus Medicines
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Paige.ai (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patents for (1) targeting mutant ER with ER PROTACS and (2) detecting genomic and histologic alterations in breast cancer using machine learning algorithms. (Inst)
Travel, Accommodations, Expenses - BMS
 
Hannah M. Linden
Leadership - Evolent (I)
Stock and Other Ownership Interests - Evolent (I)
Consulting or Advisory Role - AstraZeneca; Context Therapeutics; Eisai; Genomic Health; Syndax
Research Funding - Eisai; GTx (Inst); Sanofi (Inst)
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Katarina Petrakova
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Pfizer; Roche
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Pfizer; Roche
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Daiichi Sankyo/Astra Zeneca; Foundation Medicine; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Philips Healthcare; Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Peter Kabos
No Relationships to Disclose
 
Sofia A. D. S. Braga
No Relationships to Disclose
 
Valentina Boni
No Relationships to Disclose
 
Alice Gosselin
Employment - Sanofi
 
Sylvaine Cartot-Cotton
Employment - Sanofi
 
Séverine Doroumian
Employment - Sanofi
 
Marina Celanovic
Employment - Sanofi
 
Patrick Cohen
Employment - Sanofi
 
Gautier Paux
Employment - Sanofi
 
Mario Campone
Honoraria - GT1; Lilly; Novartis
Consulting or Advisory Role - Abbvie (Inst); Accord Healthcare (Inst); AstraZeneca/MedImmune (Inst); Daiichi Sankyo Europe GmbH; Lilly (Inst); Menarini; Novartis (Inst); Pfizer; Pierre Fabre (Inst); Sandoz-Novartis (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst)
Speakers' Bureau - Amgen; Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
Other Relationship - Roche